Olmesartan
olmesartan medoxomil · Brand: Benicar
Olmesartan Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults and children ≥6 years | Monotherapy or combination | FDA Approved |
Olmesartan holds a single FDA-approved indication for hypertension, without the heart failure, post-MI, or diabetic nephropathy indications carried by some other ARBs such as valsartan, losartan, or irbesartan. Its antihypertensive effect has onset within one week and is near maximal at four weeks. The ROADMAP trial (NEJM 2011) studied olmesartan 40 mg in patients with type 2 diabetes and normoalbuminuria, demonstrating a 23% delay in time to onset of microalbuminuria (HR 0.77, 95% CI 0.63–0.94, p=0.01), with 8.2% of olmesartan patients developing microalbuminuria versus 9.8% on placebo over a median 3.2 years. However, a concerning signal of increased fatal cardiovascular events in the olmesartan group (15 vs 3, p=0.01) tempered enthusiasm for this finding. Olmesartan is also uniquely associated with a sprue-like enteropathy not seen with other ARBs, warranting specific clinical vigilance.
Microalbuminuria prevention in T2DM: The ROADMAP trial demonstrated delayed onset of microalbuminuria, but the increased CV death signal and lack of FDA nephropathy indication limit this use. Not recommended as first-choice ARB for renoprotection when irbesartan or losartan (with specific nephropathy trial data) are available. Evidence quality: Moderate (ROADMAP trial, limited by CV safety concern).
Heart failure as ACE inhibitor alternative: ARBs as a class are recommended by AHA/ACC/HFSA guidelines as alternatives to ACE inhibitors in HFrEF. Olmesartan does not hold a specific HF indication and lacks dedicated HF outcome trial data. Evidence quality: High (class effect only).
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — standard initiation | 20 mg once daily | 20–40 mg once daily | 40 mg/day | Increase to 40 mg after 2 weeks if BP not at goal; doses above 40 mg have no greater effect BID dosing offers no advantage over same total dose QD |
| Hypertension — volume-depleted patient | Lower dose (consider 5 mg or 10 mg) | 20–40 mg once daily | 40 mg/day | Initiate under close medical supervision; correct volume depletion before starting if possible Particularly important in patients with impaired renal function on diuretics |
Paediatric Dosing (Hypertension, ≥6 years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Paediatric HTN — 20 to <35 kg | 10 mg once daily | 10–20 mg once daily | 20 mg/day | Increase after 2 weeks if needed; suspension available for patients unable to swallow tablets Not recommended in children <1 year (risk of abnormal kidney development) |
| Paediatric HTN — ≥35 kg | 20 mg once daily | 20–40 mg once daily | 40 mg/day | Same dosing range as adults for children ≥35 kg Not shown effective for BP lowering in children <6 years |
Olmesartan is administered as the medoxomil ester prodrug, which is completely and rapidly hydrolysed to the active form olmesartan during absorption from the GI tract. Doses above 40 mg do not confer additional blood pressure reduction, and twice-daily dosing provides no advantage over the same total daily dose given once. Food does not affect bioavailability. The 5 mg tablet is useful for lower starting doses in patients at risk of hypotension. In patients with severe renal impairment (CrCl <20 mL/min), AUC is approximately tripled, warranting cautious dosing and close monitoring. Moderate hepatic impairment increases AUC by approximately 60%. Hemodialysis pharmacokinetics have not been studied.
Pharmacology
Mechanism of Action
Olmesartan medoxomil is a prodrug that is completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and other tissues, preventing vasoconstriction, aldosterone release, cardiac stimulation, and renal sodium reabsorption. Its action is independent of the pathways for angiotensin II synthesis. Olmesartan does not inhibit ACE (kininase II), so bradykinin is not accumulated. At doses of 2.5 to 40 mg, olmesartan inhibits the pressor effects of angiotensin I infusion in a dose-related manner, with doses above 40 mg showing greater duration of effect. Repeated administration of up to 80 mg had minimal influence on aldosterone levels and no effect on serum potassium in the hypertension population.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Prodrug completely hydrolysed to olmesartan during absorption; absolute bioavailability ~26%; Tmax 1–2 h; food does not affect bioavailability; linear PK up to 320 mg single dose and 80 mg multiple dose | Low bioavailability but reliable oral absorption; no food-timing instructions needed; linear dose-response across therapeutic range |
| Distribution | Vd ~17 L; protein binding 99%; does not penetrate red blood cells; crosses blood-brain barrier poorly; crosses placenta in rats | Highly protein-bound; limited tissue distribution; very high protein binding means not effectively removed by dialysis |
| Metabolism | Virtually no further metabolism after conversion to olmesartan; no CYP involvement; parent compound is the circulating active entity | Complete absence of CYP-mediated metabolism eliminates pharmacokinetic drug interactions with CYP substrates/inhibitors — major advantage; no active or relevant metabolites |
| Elimination | t½ ~13 h (biphasic); 35–50% of absorbed dose in urine, remainder in faeces via bile; total clearance 1.3 L/h; renal clearance 0.6 L/h; steady state 3–5 days; no accumulation with QD dosing | Dual renal-biliary elimination; AUC approximately tripled in severe renal impairment (CrCl <20 mL/min); AUC ~60% higher in moderate hepatic impairment; hemodialysis PK not studied; 13-hour half-life supports once-daily dosing |
Side Effects
Olmesartan has been evaluated for safety in more than 3,825 patients and subjects, including more than 3,275 treated for hypertension in controlled trials, approximately 900 treated for at least 6 months, and more than 525 for at least one year. Events were generally mild, transient, and unrelated to dose. The side effect profile of olmesartan in hypertension trials was notably close to placebo, with only dizziness exceeding 1% above placebo.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| None at ≥10% incidence | — | No adverse effect occurred at ≥10% incidence in placebo-controlled hypertension trials; olmesartan has a remarkably clean side effect profile in this population |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness | 3% (vs 1% placebo) | Only adverse reaction exceeding 1% above placebo in controlled trials; usually transient and dose-related |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Sprue-like enteropathy | Rare (FDA warning) | Months to years after initiation | Discontinue olmesartan; consider alternative ARB; biopsy typically shows villous atrophy; symptoms include chronic severe diarrhoea and substantial weight loss; unique to olmesartan among ARBs |
| Angioedema / facial oedema | Rare (5 cases of facial oedema in trials) | Any time | Discontinue immediately; emergency airway management if needed; never rechallenge |
| Acute renal failure | Uncommon (postmarketing) | Days to weeks | Discontinue or reduce dose; evaluate for renal artery stenosis or volume depletion; monitor creatinine |
| Rhabdomyolysis (postmarketing) | Very rare | Variable | Discontinue; check CK; aggressive hydration; evaluate for concurrent nephrotoxins |
| Anaphylactic reaction (postmarketing) | Very rare | Any time | Emergency treatment; permanent discontinuation |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| All adverse events (olmesartan) | 2.4% (79/3,278) | Similar to placebo; no individual adverse event dominated as a cause for withdrawal |
| All adverse events (control) | 2.7% (32/1,179) | Olmesartan was numerically better tolerated than control in terms of withdrawal rates |
The FDA issued a specific warning about sprue-like enteropathy with olmesartan. Patients present with severe chronic diarrhoea, substantial weight loss, and electrolyte abnormalities, typically months to years after drug initiation. Intestinal biopsy often shows villous atrophy, mimicking coeliac disease, but tissue transglutaminase antibodies are negative. This reaction has not been reported with other ARBs and may be related to inhibition of TGF-β signalling in intestinal mucosa. Symptoms resolve upon olmesartan discontinuation. If a patient develops chronic diarrhoea with weight loss on olmesartan, exclude coeliac disease and other aetiologies, then consider switching to an alternative ARB.
Drug Interactions
Olmesartan undergoes virtually no CYP-mediated metabolism after its conversion from the prodrug, resulting in an exceptionally clean pharmacokinetic interaction profile. No significant interactions have been demonstrated with warfarin or digoxin in formal studies. The primary interactions are pharmacodynamic, relating to potassium homeostasis, renal haemodynamics, and dual RAAS blockade. The unique interaction with colesevelam hydrochloride (bile acid sequestrant) is noteworthy.
Monitoring
- Blood PressureEach visit; 2–4 weeks after dose changes
RoutineAntihypertensive effect has onset within 1 week and is near maximal at 4 weeks. No appreciable change in heart rate observed. Addition of a diuretic may be considered if BP not controlled. - Serum PotassiumBaseline, then periodically
RoutineRisk of hyperkalemia with RAAS blockade, particularly with concurrent K-sparing diuretics, supplements, or renal impairment. Hold if K+ >5.5 mEq/L. - Renal FunctionBaseline, 1–2 weeks after initiation, then every 3–6 months
RoutineAUC approximately tripled in severe renal impairment (CrCl <20 mL/min). Monitor creatinine and eGFR; a modest initial rise (<30%) is expected with RAAS blockade. Hemodialysis PK not studied. - GI SymptomsAt every visit; heightened vigilance with chronic diarrhoea
Trigger-basedSprue-like enteropathy unique to olmesartan; can develop months to years after initiation. Ask about chronic diarrhoea, unexplained weight loss, and electrolyte disturbances at each visit. If present, exclude coeliac disease and consider switching ARB. - Hepatic FunctionIf symptoms develop; baseline in hepatic impairment
Trigger-basedAUC increased ~60% in moderate hepatic impairment. Monitor if hepatic disease present or if symptoms of hepatic injury develop. - Volume StatusBefore initiation and during illness
Trigger-basedSymptomatic hypotension may occur in volume- or salt-depleted patients. Correct depletion before starting olmesartan. Counsel patients about sick-day management.
Contraindications & Cautions
Absolute Contraindications
- Pregnancy: Contraindicated at any stage; direct fetal toxicity (FDA Boxed Warning). Discontinue as soon as pregnancy is detected.
- Aliskiren co-administration in diabetes: Contraindicated due to increased renal, hypotensive, and hyperkalaemic risk.
Relative Contraindications (Specialist Input Recommended)
- Children <1 year of age: Not recommended due to risk of abnormal kidney development from RAAS blockade in immature kidneys.
- Bilateral renal artery stenosis or stenosis of a solitary kidney: Risk of acute renal failure from loss of efferent arteriolar tone.
- Severe volume or salt depletion: Risk of symptomatic hypotension; correct depletion before initiating or use lower starting dose under close supervision.
Use with Caution
- Severe renal impairment (CrCl <20 mL/min): AUC approximately tripled; use lower doses and monitor closely. Hemodialysis pharmacokinetics not studied.
- Moderate hepatic impairment: AUC increased ~60%; monitor closely. No data for severe hepatic impairment.
- Elderly (≥65 years): AUCss 33% higher with ~30% reduction in renal clearance; no dose adjustment required but greater sensitivity possible.
- Black patients: Generally smaller antihypertensive response as monotherapy; addition of a diuretic improves efficacy.
- History of GI symptoms or coeliac-like presentations: Risk of sprue-like enteropathy unique to olmesartan; consider alternative ARB if GI concerns exist.
When pregnancy is detected, discontinue olmesartan medoxomil as soon as possible. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus, including oligohydramnios, fetal renal failure, hypotension, skull hypoplasia, and neonatal death.
Patient Counselling
Purpose of Therapy
Olmesartan works by blocking the effects of a hormone called angiotensin II, which narrows blood vessels and causes the body to retain salt and water. By blocking this hormone, olmesartan helps relax blood vessels and lower blood pressure, reducing the risk of strokes and heart attacks over time.
How to Take
Take olmesartan once daily at the same time each day, with or without food. It may take 2 to 4 weeks to reach full blood pressure lowering effect. Do not stop taking olmesartan without consulting your doctor, even if you feel well. If you also take colesevelam (a cholesterol medication), take olmesartan at least 4 hours before colesevelam.
Sources
- Olmesartan medoxomil tablets prescribing information. Glenmark Pharmaceuticals Inc. Revised January 2023. DailyMed / Drugs.comCurrent FDA-approved prescribing information; primary source for all dosing, contraindications, adverse reactions, drug interactions, pharmacokinetic data, and sprue-like enteropathy warning.
- FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to olmesartan medoxomil. July 2013. FDA.govFDA safety communication establishing the sprue-like enteropathy warning specific to olmesartan; basis for the 5.5 labelling section.
- Haller H, Ito S, Izzo JL Jr, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–917. doi:10.1056/NEJMoa1007994ROADMAP trial (n=4,447); olmesartan 40 mg delayed microalbuminuria onset by 23% (HR 0.77, p=0.01) but raised concern with higher fatal CV events (15 vs 3, p=0.01).
- Haller H, Menne J, Ito S, et al. The ROADMAP Observational Follow-Up Study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc. 2014;3(5):e000810. doi:10.1161/JAHA.114.000810ROADMAP follow-up study (n=1,758); demonstrated sustained renoprotective benefit and confirmed microalbuminuria as predictor of CV events (1.8-fold higher risk).
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006US hypertension guideline positioning ARBs as first-line agents; olmesartan included as an appropriate option for blood pressure management.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071. doi:10.1097/HJH.0000000000003480European hypertension guideline recommending ARBs as first-line antihypertensive agents; discusses RAAS blockade in the context of renoprotection.
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314. doi:10.1016/j.kint.2023.10.018CKD guideline recommending RAAS blockade for renoprotection; notes class effect of ARBs though specific nephropathy trial data strongest for irbesartan and losartan.
- Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732–738. doi:10.1016/j.mayocp.2012.06.003Landmark case series (22 patients) identifying the association between olmesartan and sprue-like enteropathy with villous atrophy; all patients improved after olmesartan discontinuation.
- Ianiro G, Bibbò S, Montalto M, et al. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16–23. doi:10.1111/apt.12790Systematic review of olmesartan-associated enteropathy confirming the clinical pattern, negative coeliac serology, villous atrophy, and proposed TGF-β inhibition mechanism.
- Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41(5):515–527. doi:10.1177/00912700122010348Foundational PK study establishing bioavailability (~26%), half-life (~13h), biphasic elimination, and linear dose-response of olmesartan medoxomil.
- Warner GT, Jarvis B. Olmesartan medoxomil. Drugs. 2002;62(9):1345–1353. doi:10.2165/00003495-200262090-00005Comprehensive pharmacological review of olmesartan covering PK in special populations, dose-ranging data, and comparative efficacy with other ARBs at launch.